Related references
Note: Only part of the references are listed.Heart Disease and Stroke Statistics-2016 Update A Report From the American Heart Association
Dariush Mozaffarian et al.
CIRCULATION (2016)
Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
Dhruv S. Kazi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Patient adherence to generic versus brand statin therapy after acute myocardial infarction: Insights from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines Registry
Emily C. O'Brien et al.
AMERICAN HEART JOURNAL (2015)
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
Erik S. Stroes et al.
EUROPEAN HEART JOURNAL (2015)
Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease
Ankur Pandya et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1-Full Report
Terry A. Jacobson et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2015)
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Impact of Stalin Adherence on Cardiovascular Morbidity and All-Cause Mortality in the Primary Prevention of Cardiovascular Disease: A Population-Based Cohort Study in Finland
Piia K. Rannanheimo et al.
VALUE IN HEALTH (2015)
Cardiovascular Risk and Statin Use in the United States
Michael Edward Johansen et al.
ANNALS OF FAMILY MEDICINE (2014)
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Neil J. Stone et al.
CIRCULATION (2014)
The State of US Health, 1990-2010 Burden of Diseases, Injuries, and Risk Factors
Christopher J. L. Murray et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Forecasting the Future of Stroke in the United States A Policy Statement From the American Heart Association and American Stroke Association
Bruce Ovbiagele et al.
STROKE (2013)
Efficacy and Safety of Vorapaxar in Patients With Prior Ischemic Stroke
David A. Morrow et al.
STROKE (2013)
Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials
Doralisa Morrone et al.
ATHEROSCLEROSIS (2012)
Forecasting the Future of Cardiovascular Disease in the United States A Policy Statement From the American Heart Association
Paul A. Heidenreich et al.
CIRCULATION (2011)
Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia
F. van Nooten et al.
NETHERLANDS HEART JOURNAL (2011)
Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland
Erkki J. O. Soini et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis
Deepak L. Bhatt et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
Projected Cost-Effectiveness of Ezetimibe/Simvastatin Compared with Doubling the Statin Dose in the United Kingdom: Findings from the INFORCE Study
John Reckless et al.
VALUE IN HEALTH (2010)
Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation Introduction
R. Ara et al.
HEALTH TECHNOLOGY ASSESSMENT (2009)
Cost Effectiveness of Ezetimibe in Patients with Cardiovascular Disease and Statin Intolerance or Contraindications A Markov Model
Roberta Ara et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2008)
Cost-Effectiveness of Intensive Atorvastatin Treatment in High-Risk Patients Compared with Usual Care in a Postgeneric Statin Market: Economic Analysis of the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) Study
C. Daniel Mullins et al.
CLINICAL THERAPEUTICS (2008)
Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy
D. P. Mikhailidis et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease
Paul S. Chan et al.
CIRCULATION (2007)
The REduction of Atherothrombosis for Continued Health (REACH) Registry:: An international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design
EM Ohman et al.
AMERICAN HEART JOURNAL (2006)
Share Paper
